These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 17428299
1. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group. Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299 [Abstract] [Full Text] [Related]
2. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [Abstract] [Full Text] [Related]
3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
4. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR. Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252 [Abstract] [Full Text] [Related]
5. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group. Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321 [Abstract] [Full Text] [Related]
6. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group. Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567 [Abstract] [Full Text] [Related]
7. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Blumenfeld AM, Schim JD, Chippendale TJ. Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502 [Abstract] [Full Text] [Related]
8. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C. Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693 [Abstract] [Full Text] [Related]
9. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group. J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329 [Abstract] [Full Text] [Related]
10. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Mathew NT, Kailasam J, Meadors L. Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356 [Abstract] [Full Text] [Related]
11. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314 [Abstract] [Full Text] [Related]
12. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417 [Abstract] [Full Text] [Related]
13. Botulinum toxin type A in prophylactic treatment of migraine. Anand KS, Prasad A, Singh MM, Sharma S, Bala K. Am J Ther; 2006 Apr; 13(3):183-7. PubMed ID: 16772757 [Abstract] [Full Text] [Related]
14. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Freitag FG, Diamond S, Diamond M, Urban G. Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229 [Abstract] [Full Text] [Related]
15. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW. Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312 [Abstract] [Full Text] [Related]
16. Duration of migraine is a predictor for response to botulinum toxin type A. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566 [Abstract] [Full Text] [Related]
17. Botulinum toxin type A for the treatment of nummular headache: four case studies. Mathew NT, Kailasam J, Meadors L. Headache; 2008 Mar; 48(3):442-7. PubMed ID: 18028377 [Abstract] [Full Text] [Related]
18. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291 [Abstract] [Full Text] [Related]
19. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP, Study Group. Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595 [Abstract] [Full Text] [Related]